Bourgeon Capital Management LLC Has $948,000 Stock Position in Amgen Inc. $AMGN

Bourgeon Capital Management LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 91.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,396 shares of the medical research company’s stock after selling 36,278 shares during the quarter. Bourgeon Capital Management LLC’s holdings in Amgen were worth $948,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Brighton Jones LLC increased its position in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its position in Amgen by 36.3% during the first quarter. Fifth Third Wealth Advisors LLC now owns 6,185 shares of the medical research company’s stock worth $1,927,000 after buying an additional 1,647 shares during the last quarter. Mirador Capital Partners LP increased its position in Amgen by 6.0% during the first quarter. Mirador Capital Partners LP now owns 1,116 shares of the medical research company’s stock worth $348,000 after buying an additional 63 shares during the last quarter. Fiduciary Alliance LLC increased its position in Amgen by 0.9% during the first quarter. Fiduciary Alliance LLC now owns 29,168 shares of the medical research company’s stock worth $9,087,000 after buying an additional 262 shares during the last quarter. Finally, NBC Securities Inc. increased its position in Amgen by 111,133.3% during the first quarter. NBC Securities Inc. now owns 6,674 shares of the medical research company’s stock worth $2,079,000 after buying an additional 6,668 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.69% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AMGN. Morgan Stanley boosted their price objective on Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. UBS Group reduced their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Cantor Fitzgerald restated a “neutral” rating and set a $305.00 price objective on shares of Amgen in a report on Tuesday, June 24th. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. Finally, Piper Sandler boosted their price objective on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a report on Monday, August 25th. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $309.70.

Amgen Stock Up 0.4%

NASDAQ AMGN opened at $273.97 on Tuesday. The business has a fifty day moving average price of $288.42 and a two-hundred day moving average price of $288.61. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $335.88. The stock has a market capitalization of $147.49 billion, a PE ratio of 22.40, a PEG ratio of 2.37 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were paid a $2.38 dividend. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.5%. Amgen’s dividend payout ratio (DPR) is 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.